Premature treatment cessation in pediatric acute myeloid leukemia due to excessive toxicity: clinical experiences and patient outcomes - a case series.
AI interpretation is pending for this paper.
Open original publication →What the AI sees
Not AI summarized yet.
Research significance
Pending deeper interpretation.
Source abstract
Although survival in pediatric acute myeloid leukemia (AML) has improved over the past decades, intensive chemotherapy may be associated with severe and life-threatening toxicities. This case series describes pediatric AML patients in whom therapy was discontinued due to excessive toxicity. Patients were identified through a national database of two consecutive AML treatment protocols in the Netherlands (2010-2023). Seven patients were included; discontinuation of treatment was because of a severe fungal infection in five out of seven cases. Five out of seven patients had a favorable genetic profile; four harboring RUNX1::RUNX1T1 and one with a CEBPA-bZIP mutation. All seven patients remain in continuous complete remission with a median follow-up of 6,7 years. This case series shows that selected children with AML who discontinue chemotherapy early due to treatment-related toxicity may still achieve long-term survival and possibly cure. The high incidence of invasive fungal infections highlights a critical cause of treatment-limiting toxicity. This series could inform clinical practice in future similar cases.